Research programme: small molecule therapeutics - Neurokine Therapeutics
Latest Information Update: 16 Mar 2022
At a glance
- Originator NeuroKine Therapeutics
- Class Small molecules
- Mechanism of Action Protein-serine-threonine kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 01 Mar 2022 Preclinical trials in CNS disorders in USA (unspecified route), prior to March 2022 (NeuroKine Therapeutics pipeline, March 2022)